ERBB2 and neoplasm: Likewise, cells spared by BRAF, HER2 and PI3K inhibition maintained the capacity to generate secondary tumors and re-grow following conclusion of treatment, even though reductions of CD44v6 expression and sphere-forming ability were observed in primary tumor xenograft-derived cells [17].